Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in ...
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
Topline data were announced from a phase 3 trial evaluating Keytruda plus Lenvima with chemotherapy in advanced gastroesophageal cancer.
1d
KLBK Lubbock on MSNUMC, TTUHSC announces groundbreaking findings to shrink tumors, prolong survival in Kidney Cancer patientsA groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...
The evaluation of therapeutic outcomes of percutaneous US/CT-guided bipolar radiofrequency ablation for small renal masses under local anesthesia. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Trends in kidney cancer: Exploring the impact of sex and age on stage of disease, and prognosis during the past three decades in Denmark—A DaRenCa study. This is an ASCO Meeting Abstract from the 2025 ...
Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...
Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a form of renal cell carcinoma (RCC) driven by a mostly inherited mutation.
Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus ...
Glasgow Times on MSN2d
Drug combination nearly erases liver cancer in major breakthroughA groundbreaking cancer study led by Professor Tom Bird from the Cancer Research UK Scotland Institute has discovered a drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results